Clinical Trial Protocol
Iranian Registry of Clinical Trials

17 Sep 2026

Celecoxib in the treatment of depression in patients with Brucellosis: a double blind randomized trial

Protocol summary

Summary

The purpose of the present investigation is to assess the efficacy of celecoxib in the treatment of mild to moderate among patients with brucellosis in a eight-week double-blind, placebo controlled trial. 50 adult outpatients who meet the DSM-V criteria for major depression(mild to moderate) will participate in the trial. Patients who have a baseline Hamilton Rating Scale for Depression score below 20 will be randomly allocated into two groups. 25 persons will receive Cap. rifampin (600 to 900 mg/day)+ Doxycycline100 mg bid+ cap. celecoxib 200 mg bid for 8 weeks. 25 patients will receive Cap. rifampin (600 to 900 mg/day)+ Doxycycline100 mg bid+ placebo for 8 weeks. Patients will be assessed by a psychiatrist at baseline and after 2, 4 and 8 weeks after the medication started. Efficacy will be defined as the change from baseline to endpoint in score on Hamilton Rating Scale for Depression.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201405271556N59**
Registration date: **2014-05-29, 1393/03/08**
Registration timing: **prospective**

Last update:
Update count: **0**

Registration date

2014-05-29, 1393/03/08

Registrant information

Name
Shahin Akhondzadeh
Name of organization / entity
Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 5541 2222
Email address
s.akhond@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source
Tehran University of Medical Sciences

Expected recruitment start date

2014-06-22, 1393/04/01

Expected recruitment end date

2016-06-20, 1395/03/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Celecoxib in the treatment of depression in patients with Brucellosis: a double blind randomized trial

Public title

celecoxib in the treatment of depressed patients with brucellosis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: 1-Confirmation of brucellusis, 2age between 18 to 50 years old, 3- score lower than 20 in Hamilton Rating Scale for depression 4-Mild to moderate major depressive disorder based on DSM-V Exclusion criteria: 1-duration of brucellosis more than 3 months, 2-presence of localized brucellosis(including endocarditis, osteomyelitis), 3-psychotic disorder, 4-receiving psychotropic medications, 5-receiving antidepressants during the last month 6-receiving antibiotics during the

last month, 7-patients who are under treatment with immunosuppressives, 8-history of cardiovascular disease, 9-pregnancy, 10-nursing women, 11-any significant medical condition(including malignancy, HIV infection, autoimmune disease,renal failure,hepatic failure), 12- other infectious diseases

Age
From **18 years** old to **50 years** old

Gender
Both

Phase
N/A

Groups that have been masked
No information

Sample size
Target sample size: **50**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Double blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ethics Committee of Tehran University of Medical Sciences

Street address
Keshvarz Blvd

City
Tehran

Postal code

Approval date
2014-05-01, 1393/02/11

Ethics committee reference number
24320

Health conditions studied

1

Description of health condition studied
Major depressive disorder

ICD-10 code
F32

ICD-10 code description
Major Depressive episode

Primary outcomes

1

Description
Severity of depression

Timepoint
Baseline and weeks 2-4-8 after beginig of treatment

Method of measurement
by Hamiltion Depression Rating Scale 17-Item

Secondary outcomes

empty

Intervention groups

1

Description
Capsule Rifampine(900 mg/day in individuals with 75 kg weight or more and 600 mg/day in individuals with weight less than 75 kg)+ Cap. Doxycycline(100 mg bid)+ cap. celecoxib(200 mg bid) for 8 weeks

Category
Treatment - Drugs

2

Description
Capsule Rifampine(900 mg/day in individuals with 75 kg weight or more and 600 mg/day in individuals with weight less than 75 kg)+ Cap. Doxycycline(100 mg bid)+ cap. placebo for 8 weeks

Category
Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center
Roozbeh Hospital

Full name of responsible person
Prof. Shahin Akhondzadeh

Street address
South Kregar street, Roozbeh Hospital

City
Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Tehran University of Medical Sciences

Full name of responsible person
Dr masoud yunesian

Street address
Keshvarz Blvd

City
Tehran
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Kargar street; Roozbeh Hospital
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
s.akhond@sina.tums.ac.ir
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Kargar Street; Roozbeh Hospital
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
s.akhond@sina.tums.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Karegar street; Roozbeh Hospital
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
s.akhond@sina.tums.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty